Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminocaproic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG known ✓ | P00747 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | THRB | P10828 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.90 |
| ▸ | RECQL | P46063 | 1/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 6/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.70 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.70 |
| ▸ | GABRP | O00591 | 1/20 | 0.70 |
| ▸ | GABRD | O14764 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminocaproic Acid SCHEMBL4909921 | 1.00 | LMNA (0.90) | LMNAKMT2AALDH1A1THRBMEN1 | |
| Octanedioate SCHEMBL261455 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| SCHEMBL14322257 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| 12-Aminododecanoic Acid SCHEMBL8973700 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| SCHEMBL1876262 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| SCHEMBL2778601 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| Aminocaproic Acid SCHEMBL21141584 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| Pimelic Acid SCHEMBL21465298 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| 12-Aminododecanoic Acid SCHEMBL20767098 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 | |
| Adipic Acid SCHEMBL10591067 | 0.95 | LMNA (1.00) | LMNAKMT2AALDH1A1THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284426-A | Ophthalmic compositions and methods of use thereof | 塔西亚制药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-8877725-B2 | Peptide conjugated, inosine-substituted antisense oligomer compound and method | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130131312-A1 | PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD | AVI BIOPHARMA, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8053420-B2 | Peptide conjugated, inosine-substituted antisense oligomer compound and method | AVI BIOPHARMA, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1765414-B1 | PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD | AVI BIOPHARMA INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20080182973-A1 | Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis | AVI BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| EP-1765414-A2 | PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD | Avi Biopharma, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050288246-A1 | Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis | SAREPTA THERAPEUTICS, INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005115479-A2 | PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD | AVI BIOPHARMA, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288246-A1 | Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis | PKD1, PCNA, SLC7A1 | PLG 1356/4885LMNA 4129/4885KMT2A 3482/4885 |
| US-20080182973-A1 | Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis | PKD1, PCNA, SLC7A1 | PLG 1361/4885LMNA 4124/4885KMT2A 3475/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | PLG 904/4885LMNA 563/4885KMT2A 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.